Detalhe da pesquisa
1.
Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers.
Support Care Cancer
; 24(2): 621-627, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26111957
2.
Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study.
Br J Clin Pharmacol
; 80(3): 446-59, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26011050
3.
ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies.
Br J Clin Pharmacol
; 75(4): 959-65, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22905923
4.
Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens.
Clin Pharmacol Ther
; 112(4): 873-881, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35687528
5.
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Lancet Infect Dis
; 21(7): 975-983, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33587897
6.
ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies.
Br J Clin Pharmacol
; 79(3): 456-64, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25060671
7.
No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.
Br J Clin Pharmacol
; 69(4): 401-10, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20406224
8.
Replacing the thorough QT study: reflections of a baby in the bath water.
Br J Clin Pharmacol
; 78(2): 195-201, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24286381
9.
A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.
Clin Pharmacol Drug Dev
; 8(1): 49-59, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29786964
10.
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Postgrad Med
; 129(1): 69-80, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27927048
11.
Benefits of Centralized ECG Reading in Clinical Oncology Studies.
Ther Innov Regul Sci
; 50(1): 123-129, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30236011
12.
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Chest
; 128(5): 3398-406, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16304291
13.
Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.
Drug Saf
; 38(8): 693-710, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26008987
14.
Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
Cancer Chemother Pharmacol
; 76(1): 211-6, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26006703
15.
Evaluation of vardenafil and sildenafil on cardiac repolarization.
Am J Cardiol
; 93(11): 1378-83, A6, 2004 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15165918
16.
Electrocardiographic effects of rivastigmine.
J Clin Pharmacol
; 42(5): 558-68, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12017350
17.
The pharmacokinetics and safety of single escalating oral doses of eletriptan.
J Clin Pharmacol
; 42(5): 520-7, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12017346
18.
Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects.
J Clin Pharmacol
; 44(7): 689-95, 2004 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15199073
19.
Electrocardiographic response to intravenous and intraarterial injection of iosimenol (a new, iodinated, non-ionic, iso-osmolar contrast medium).
J Invasive Cardiol
; 25(11): 573-8, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24184891
20.
Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.
Drug Saf
; 36(7): 491-503, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23620168